SCHEMBL7983473

SCHEMBL7983473

Nc1ccc(N2CCC(=O)C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.48
ALDH1A1 P00352 9/20 0.48
GAA P10253 5/20 0.48
KDM4E B2RXH2 5/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
HTT P42858 2/20 0.48
RECQL P46063 2/20 0.48
NPC1 O15118 1/20 0.48
USP2 O75604 1/20 0.48
TP53 P04637 1/20 0.48
POLB P06746 1/20 0.48
THRB P10828 1/20 0.48
ALOX15 P16050 1/20 0.48
RAB9A P51151 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GFER P55789 5/20 0.47
LMNA P02545 5/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77364 0.88 MAPT (0.57) MAPTALDH1A1GAAKDM4EKMT2A
Hydrochloric Acid SCHEMBL6073799 0.86 MAPT (0.61) MAPTALDH1A1GAAKDM4EKMT2A
SCHEMBL10408293 0.80 HTR3E (0.47) ALDH1A1KMT2AMEN1HTTLMNA
SCHEMBL568685 0.80 MAOB (0.49) MAPTALDH1A1KDM4EHTTNPC1
SCHEMBL10407318 0.80 AKR1C3 (0.41) MAPTKDM4EKMT2AMEN1L3MBTL1
SCHEMBL9832282 0.80 ADRB1 (0.47) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL1953072 0.79 MEN1 (0.45) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL1269255 0.77 PIK3CA (0.43) MAPTKDM4EKMT2AMEN1POLB
SCHEMBL25258039 0.76 TP53BP1 (0.35) KMT2AMEN1L3MBTL1MAOBTP53BP1
SCHEMBL4580340 0.76 CA12 (0.53) MAPTALDH1A1KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 MAPT 1771/4885ALDH1A1 2813/4885GAA 1536/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 MAPT 2950/4885ALDH1A1 318/4885GAA 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.